In Vitro Activity of New β-Lactamase Inhibitor Combinations against <i>bla</i><sub>NDM</sub>, <i>bla</i><sub>KPC</sub>, and ESBL-Producing Enterobacteriales Uropathogens

In Vitro Activity of New β-Lactamase Inhibitor Combinations against <i>bla</i><sub>NDM</sub>, <i>bla</i><sub>KPC</sub>, and ESBL-Producing Enterobacteriales Uropathogens

Antibiotic resistance in uropathogens has increased substantially and severely affected treatment of urinary tract infections (UTIs). Lately, some new formulations, including meropenem/vaborbactam (MEV), ceftazidime/avibactam (CZA), and ceftolozane/tazobactam (C/T) have been introduced to treat infe...

Full description

Bibliographic Details
Main Authors: Lubna Razaq, Fakhur Uddin, Shahzad Ali, Shah Muhammad Abbasi, Muhammad Sohail, Nabila E. Yousif, Hala M. Abo-Dief, Zeinhom M. El-Bahy
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Antibiotics
Subjects:
meropenem/vaborbactam
ceftazidime/avibactam
<i>Klebsiella pneumoniae</i> carbapenemase
New Delhi metallo-β-lactamase
Online Access:https://www.mdpi.com/2079-6382/12/10/1481

Internet

https://www.mdpi.com/2079-6382/12/10/1481

Similar Items